Quadriga BioSciences, Inc.

DENVER, Aug. 15, 2023 /PRNewswire/ -- Quadriga Partners, LLC ("Quadriga"), an investment bank and transaction advisory group that works exclusively with companies in the healthcare industry, advised OrthoNebraska (the "Company") on its partnership with InTandem Capital Partners ("InTandem"). Continue Reading Based in Omaha, Nebraska, OrthoNebraska is a leading orthopedic practice with more than 25 specialty-trained physicians. The Company is a vertically integrated orthopedic system providing musculoskeletal care throughout its continuum of outpatient clinics and physical therapy clinics, as well as OrthoNebraska Hospital, one of Nebraska's leading specialty orthopedic hospitals. OrthoNebraska's comprehensive services include orthopedic surgery, urgent care, emergency care, physical therapy, advanced imaging, durable medical equipment, and sports training. Quadriga Partners advised OrthoNebraska on its partnership with InTandem Capital Partners. Tweet this InTandem's investment in OrthoNebraska will create a preeminent musculoskeletal platform serving the Upper Midwest. The platform will look to leverage the Company's sterling reputation to expand care throughout Nebraska and to surrounding states. Levi Scheppers, CEO of OrthoNebraska, explained, "From the onset of the process, we were most interested in finding the right partner, one that shared our values and our goals. Fortunately, Jason and his team embody these same values and goals, so it was not surprising they were able to find a future partner that aligned so well with the ethos of OrthoNebraska. The thorough process that Jason and his team lead us through resulted in something we are all extremely proud of, especially as we look to what this means for the future of musculoskeletal care in the Midwest." Jason Ficken, Managing Partner of Quadriga, added, "OrthoNebraska was truly the ideal client, from the size and complexity of the practice to the sophistication of the executive team to the unwavering engagement of the physician partners. Simply put, it was a privilege to walk shoulder to shoulder with each member of the OrthoNebraska team on this journey. We remain committed to continue supporting their unique trajectory well into the future." For additional information, please contact Jason Ficken at [email protected] | (720) 810-2170 or Shane Guenther at [email protected] | (970) 275-3566 About Quadriga Partners: Quadriga is a middle-market investment bank that works exclusively with companies in the healthcare industry. Headquartered in Denver, Colorado, Quadriga provides mergers and acquisitions, capital raising, and strategic advisory services. For additional information on Quadriga, please visit . About OrthoNebraska: OrthoNebraska is an innovative musculoskeletal health system based in Omaha, Nebraska. OrthoNebraska provides comprehensive orthopedic care through its network of outpatient clinics and specialty hospital. For additional information on OrthoNebraska, please visit . About InTandem: InTandem Capital Partners is a private equity firm that invests in and helps accelerate the growth of small to mid-sized companies in select healthcare services sectors. InTandem provides active support to the management of its portfolio companies and leverages its network of industry executives to augment its capabilities. For additional information on InTandem, please visit . SOURCE Quadriga Partners, LLC

4月12日，Quadriga BioSciences宣布，其针对性治疗癌症的自研药品QBS10072S（QBS72S）的首位Ⅱ期研究受试者已经入院，以评估其用于乳腺癌的脑转移治疗的有效性。 乳腺癌常被称为“粉红杀手”，其发病率位居女性恶性肿瘤的首位。据2018年国际癌症研究机构（IARC）调查的最新数据显示，乳腺癌在全球女性癌症中的发病率为24.2%，位居女性癌症的首位，其中52.9%发生在发展中国家。在容易发生脑转移的癌症中，乳腺癌仅次于肺癌，排在第二位，其中又以HER2阳性乳腺癌或者三阴性乳腺癌发生脑转移最为常见。乳腺癌发生脑转移，说明已经处于晚期，预后较差。目前尚无乳腺癌脑转移的治愈手段，一般采取积极治疗，包括化疗、内分泌治疗和生物治疗等全身综合治疗。 小分子偶联药物（SMDC）是由小分子的靶向配体与细胞毒药物偶联所得，由三部分构成：小分子靶向配体、细胞毒分子和连接子。与ADC（抗体偶联药物）相比，SMDC能更快速均匀地分散到肿瘤组织中，且成本低、无免疫原性。与体积较大的ADC 相比，小分子配体未与受体结合的SMDC 更能快速地从体内排泄，避免长时间血液循环导致细胞毒药物释放引起的不良反应；此外，由于SMDC所用的连接基一般是可断裂的，能够在几分钟至1 h 内快速地与受体结合及被肾脏清除，因此SMDC 对连接基的稳定性要求与需要在血液中循环较长时间的ADC 相比较低，一般只要求能保持几分钟至1 h 的稳定性。 大多数乳腺癌的治疗方法在脑转移时有效性有限，部分原因是目前的化疗药物无法以足够的浓度穿过血脑屏障。QBS72S是Quadriga开发的一款靶向LAT1的全球首创新型双功能小分子偶联药物。该在研药经由LAT1高效、主动地透过血脑屏障转运至大脑，并选择性地进入LAT1高表达的肿瘤细胞，同时也使得通常不表达LAT1的正常组织免受损伤。在肿瘤细胞内，QBS72S通过干扰快速分裂的肿瘤细胞的DNA复制发挥其细胞杀伤活性，从而杀死肿瘤。 本次开展的Ⅱ期开放标签临床试验旨在评估QBS72S对乳腺癌脑转移患者的安全性、耐受性和疗效。该研究将招募多达35名患者，主要终点是通过总反应率确定初步疗效。次要终点包括测量无进展生存期、总生存期、反应时间和不良事件。 此外，在Dana-Farber癌症研究所进行的INSIGhT Ⅱ期研究中，QBS72S也正在作为潜在的胶质母细胞瘤治疗方法进行评估。这两个Ⅱ期研究都获得了小企业创新研究基金（SBIR）的资助。乳腺癌的研究得到了加利福尼亚乳腺癌研究计划的支持。 Quadriga BioSciences首席执行官Gordon Ringold博士表示：“在肿瘤学领域，脑转移的治疗是一个重要的未满足需求，因为目前尚未批准任何治疗方案。QBS72S具有通过血脑屏障，针对癌细胞的能力，有望改善这些患者的疗效。我们期待与斯坦福医学的同事们更近一步地开展调查。” 斯坦福医学的神经外科教授、斯坦福脑瘤中心联合主任、Ⅱ期临床研究的首席研究员Melanie Hayden Gephart博士表示，“乳腺癌是最常见的转移至大脑的肿瘤之一。乳腺癌脑转移会恶化预后，对生活质量产生负面影响，目前可用的治疗手段有限。QBS72S在临床前研究中已显示出治疗希望，因为其具有针对性的作用机制。我期待这个药物能够为有需要的患者带来帮助。” 参考资料： https://www.quadrigabiosciences.com/wp-content/uploads/2023/04/Quadriga-First-Patient-In-Stanford-Study-FINAL.pdf

LOS ALTOS, Calif., April 11, 2023 /PRNewswire/ -- Quadriga BioSciences, a clinical-stage oncology company developing QBS10072S (QBS72S) for the targeted treatment of cancer, today announced the dosing of the first subject in a Phase 2 study evaluating QBS72S for the treatment of brain metastases of breast cancers. "The treatment of brain metastases is a significant unmet need in oncology, as no approved therapies exist," said Gordon Ringold, Ph.D., Chief Executive Officer of Quadriga BioSciences. "With its ability to cross the blood brain barrier and target cancer cells, QBS72S has the potential to improve outcomes in these patients. We look forward to investigating this more closely with our colleagues at Stanford Medicine." Most therapies for breast cancer have limited efficacy when metastasized to the brain, due in part to the inability for current chemotherapeutics to cross the blood brain barrier (BBB) in sufficient concentrations. "Breast cancer is one of the most common tumors to metastasize to the brain. Breast cancer brain metastases worsen prognosis, negatively affect quality of life, and currently available treatments are limited," said Melanie Hayden Gephart, M.D., Professor of Neurosurgery at Stanford Medicine, co-director of the Stanford Brain Tumor Center, and Principal Investigator of the Phase 2 clinical study. "QBS72S has shown promise in preclinical studies due to its targeted mechanism of action. I look forward to the opportunity to investigate this compound for patients in need." QBS72S is also being investigated as a potential glioblastoma treatment in the Phase 2 INSIGhT study at the Dana-Farber Cancer Institute (find more information here). The two Phase 2 studies are each funded by Small Business Innovation Grants (SBIR). The breast cancer study received initial support from the California Breast Cancer Research Program. About QBS72S QBS72S is a novel, first-in-class chemotherapeutic agent that mimics an aromatic amino acid for cellular uptake by the amino acid transporter LAT1 (L-type amino acid transporter 1) thereby enabling the drug to cross the blood brain barrier (BBB) as well as to selectively target numerous types of rapidly growing cancer cells. Once inside the cell QBS72S causes double-stranded DNA breaks resulting in cell death. Most aggressive cancers express high LAT1, which is commonly associated with poor prognoses.1 About the Study The Phase 2 open-label clinical trial is designed to assess the safety, tolerability and efficacy of QBS72S in patients with brain metastases from breast cancer. The study will recruit up to 35 patients with the primary objective of determining preliminary efficacy through overall response rate. Secondary endpoints include measurement of progression free survival, overall survival, duration of response, and adverse events. Please refer to [NCT05305365] for additional clinical trial details. About Quadriga BioSciences Quadriga BioSciences is a clinical-stage oncology company developing QBS10072S (QBS72S), a novel, first-in-class chemotherapeutic agent that exploits the amino acid transporter LAT1, enabling the drug to cross the blood brain barrier (BBB) as well as to selectively target numerous types of rapidly growing cancer cells. Our technology is based on the discovery that many aggressive forms cancer cells overexpress LAT1 on their cell surfaces for the intake of nutrients to support rapid tumor growth and proliferation. Our mission is to develop safer and more effective treatments for patients with cancer. For more information, please visit . Contact Information General Inquiries [email protected] +1 (650) 917 9098 Media Inquiries David Melamed, Ph.D. [email protected] +1 (212) 845-4225 SOURCE Quadriga BioSciences, Inc.